» Articles » PMID: 24473361

Exploration of Liver Cancer Genomes

Overview
Specialty Gastroenterology
Date 2014 Jan 30
PMID 24473361
Citations 110
Authors
Affiliations
Soon will be listed here.
Abstract

Liver cancer is the third leading cause of cancer-related death worldwide. Advances in sequencing technologies have enabled the examination of liver cancer genomes at high resolution; somatic mutations, structural alterations, HBV integration, RNA editing and retrotransposon changes have been comprehensively identified. Furthermore, integrated analyses of trans-omics data (genome, transcriptome and methylome data) have identified multiple critical genes and pathways implicated in hepatocarcinogenesis. These analyses have uncovered potential therapeutic targets, including growth factor signalling, WNT signalling, the NFE2L2-mediated oxidative pathway and chromatin modifying factors, and paved the way for new molecular classifications for clinical application. The aetiological factors associated with liver cancer are well understood; however, their effects on the accumulation of somatic changes and the influence of ethnic variation in risk factors still remain unknown. The international collaborations of cancer genome sequencing projects are expected to contribute to an improved understanding of risk evaluation, diagnosis and therapy for this cancer.

Citing Articles

Tumor Intrinsic Immunogenicity Suppressor SETDB1 Worsens the Prognosis of Patients with Hepatocellular Carcinoma.

Yin C, Song C Cells. 2025; 13(24.

PMID: 39768193 PMC: 11675013. DOI: 10.3390/cells13242102.


A novel gene signature based on endoplasmic reticulum stress for predicting prognosis in hepatocellular carcinoma.

Du X, He Y, Dong P, Yan C, Wei Y, Yao H Transl Cancer Res. 2024; 13(9):4574-4592.

PMID: 39430815 PMC: 11483465. DOI: 10.21037/tcr-24-191.


Leveraging Patient-Derived Organoids for Personalized Liver Cancer Treatment.

Rao J, Song C, Hao Y, Chen Z, Feng S, Xu S Int J Biol Sci. 2024; 20(13):5363-5374.

PMID: 39430248 PMC: 11488587. DOI: 10.7150/ijbs.96317.


Tumor cell-intrinsic MELK enhanced CCL2-dependent immunosuppression to exacerbate hepatocarcinogenesis and confer resistance of HCC to radiotherapy.

Tang B, Zhu J, Shi Y, Wang Y, Zhang X, Chen B Mol Cancer. 2024; 23(1):137.

PMID: 38970074 PMC: 11225310. DOI: 10.1186/s12943-024-02049-0.


Hepatocyte transformation is induced by laminin γ2 monomer.

Funahashi N, Okada H, Kaneko R, Nio K, Yamashita T, Koshikawa N Cancer Sci. 2024; 115(9):2972-2984.

PMID: 38951133 PMC: 11462950. DOI: 10.1111/cas.16265.